Board Change • May 01
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Non-Executive Director Dirk van Dissel was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Dec 24
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Non-Executive Director Dirk van Dissel was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Nov 27
Anatara Lifesciences Ltd has completed a Follow-on Equity Offering in the amount of AUD 1.2 million. Anatara Lifesciences Ltd has completed a Follow-on Equity Offering in the amount of AUD 1.2 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 33,647,583
Price\Range: AUD 0.012
Discount Per Security: AUD 0.00072
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 59,685,751
Price\Range: AUD 0.012
Discount Per Security: AUD 0.00072
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 6,666,666
Price\Range: AUD 0.012
Transaction Features: Subsequent Direct Listing Announcement • Oct 02
Anatara Lifesciences Ltd has filed a Follow-on Equity Offering in the amount of AUD 1.2 million. Anatara Lifesciences Ltd has filed a Follow-on Equity Offering in the amount of AUD 1.2 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 33,647,583
Price\Range: AUD 0.012
Discount Per Security: AUD 0.00072
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 59,685,751
Price\Range: AUD 0.012
Discount Per Security: AUD 0.00072
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 6,666,666
Price\Range: AUD 0.012
Transaction Features: Subsequent Direct Listing Announcement • Sep 15
Anatara Lifesciences Ltd, Annual General Meeting, Nov 20, 2025 Anatara Lifesciences Ltd, Annual General Meeting, Nov 20, 2025. Announcement • Feb 28
Anatara Lifesciences Ltd Announces Board Changes Anatara Lifesciences announced the resignation of non-executive director Mr. Nicholas Haslam due to other business commitments, effective immediately. Mr. Jonathan Lindh has been appointed as a non-executive director that will accompany his continuing role as Company Secretary. Jonathan Lindh is a lawyer with over 15 years of legal and company secretarial experience. He has worked in private practice for Australian and international law firms, and for a boutique corporate advisory business. Jonathan has experience advising listed and unlisted private and public companies on a broad range of matters including mergers & acquisitions, divestments, capital raisings, joint ventures, supply/offtake agreements, foreign investment, corporate governance and corporate law issues. Jonathan has also served as company secretary of a number of ASX listed companies and other private and public companies operating in various industries. Announcement • Dec 20
Anatara Lifesciences Ltd has completed a Follow-on Equity Offering in the amount of AUD 0.2745 million. Anatara Lifesciences Ltd has completed a Follow-on Equity Offering in the amount of AUD 0.2745 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 5,490,000
Price\Range: AUD 0.05
Discount Per Security: AUD 0.003 Announcement • Nov 23
Anatara Lifesciences Ltd has completed a Follow-on Equity Offering in the amount of AUD 0.75 million. Anatara Lifesciences Ltd has completed a Follow-on Equity Offering in the amount of AUD 0.75 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 15,000,000
Price\Range: AUD 0.05
Discount Per Security: AUD 0.003
Transaction Features: Subsequent Direct Listing Announcement • Sep 10
Anatara Lifesciences Ltd, Annual General Meeting, Nov 14, 2024 Anatara Lifesciences Ltd, Annual General Meeting, Nov 14, 2024. Announcement • Jul 11
Anatara Lifesciences Ltd has completed a Follow-on Equity Offering in the amount of AUD 1 million. Anatara Lifesciences Ltd has completed a Follow-on Equity Offering in the amount of AUD 1 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 23,250,000
Price\Range: AUD 0.04
Discount Per Security: AUD 0.0024
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 1,750,000
Price\Range: AUD 0.04
Discount Per Security: AUD 0.0024
Transaction Features: Subsequent Direct Listing Announcement • May 01
Anatara Lifesciences Ltd has filed a Follow-on Equity Offering in the amount of AUD 1 million. Anatara Lifesciences Ltd has filed a Follow-on Equity Offering in the amount of AUD 1 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 23,250,000
Price\Range: AUD 0.04
Discount Per Security: AUD 0.0024
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 1,750,000
Price\Range: AUD 0.04
Discount Per Security: AUD 0.0024
Transaction Features: Subsequent Direct Listing Board Change • Jan 30
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. COO & Executive Director John Michailidis was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. New Risk • Dec 20
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 51% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Shareholders have been substantially diluted in the past year (51% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (AU$3.69m market cap, or US$2.50m). Announcement • Dec 11
Anatara Lifesciences Ltd has completed a Follow-on Equity Offering in the amount of AUD 1.315185 million. Anatara Lifesciences Ltd has completed a Follow-on Equity Offering in the amount of AUD 1.315185 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 16,343,136
Price\Range: AUD 0.022
Discount Per Security: AUD 0.00132
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 29,905,116
Price\Range: AUD 0.022
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 13,532,851
Price\Range: AUD 0.022
Transaction Features: Rights Offering New Risk • Dec 11
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 54% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Shareholders have been substantially diluted in the past year (54% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (AU$4.05m market cap, or US$2.66m). Board Change • Dec 04
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. COO & Executive Director John Michailidis was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Nov 04
Anatara Lifesciences Ltd has filed a Follow-on Equity Offering in the amount of AUD 1.055331 million. Anatara Lifesciences Ltd has filed a Follow-on Equity Offering in the amount of AUD 1.055331 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 16,343,091
Price\Range: AUD 0.022
Discount Per Security: AUD 0.00132
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 31,626,500
Price\Range: AUD 0.022
Transaction Features: Rights Offering Board Change • Nov 03
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. COO & Executive Director John Michailidis was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Sep 28
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Non-Executive Director Jane Ryan was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Sep 20
Anatara Lifesciences Ltd, Annual General Meeting, Nov 10, 2023 Anatara Lifesciences Ltd, Annual General Meeting, Nov 10, 2023, at 10:00 AUS Central Standard Time. Board Change • Aug 03
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Non-Executive Director Jane Ryan was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Jun 27
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Non-Executive Director Jane Ryan was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Jun 07
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Non-Executive Director Jane Ryan was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Apr 03
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Non-Executive Director Jane Ryan was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Mar 07
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Non-Executive Director Jane Ryan was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Feb 17
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Non-Executive Director Jane Ryan was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Dec 02
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. Executive Chairman David Brookes was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Board Change • Oct 25
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. Executive Chairman David Brookes was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Board Change • Aug 03
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. Independent Executive Chairman David Brookes was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Board Change • Jun 11
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. Independent Non-Executive Chairman David Brookes was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Board Change • May 06
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. Independent Non-Executive Chairman David Brookes was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Board Change • Mar 22
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. Independent Non-Executive Chairman David Brookes was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Board Change • Feb 25
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. Independent Non-Executive Chairman David Brookes was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Board Change • Feb 03
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. Independent Non-Executive Chairman David Brookes was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Board Change • Dec 22
High number of new directors Independent Non-Executive Chairman David Brookes was the last director to join the board, commencing their role in 2019. Recent Insider Transactions • Apr 16
Insider recently sold AU$177k worth of stock On the 13th of April, Tracey Mynott sold around 811k shares on-market at roughly AU$0.22 per share. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. Reported Earnings • Feb 24
First half 2021 earnings released: AU$0.016 loss per share (vs AU$0.036 loss in 1H 2020) First half 2021 results: Net loss: AU$1.03m (loss narrowed 43% from 1H 2020). Is New 90 Day High Low • Jan 27
New 90-day high: AU$0.22 The company is up 16% from its price of AU$0.19 on 30 October 2020. The Australian market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 5.0% over the same period.